Just Medical Secures Hundreds of Millions in Series B Funding to Accelerate Joint Disease Prevention and Treatment Ecosystem

VCBeat learned at the earliest opportunity,Just Medical Devices (Tianjin) Co., Ltd. (“Just Medical”) recently completed a Series B financing round worth hundreds of millions of yuan, co-led by Qiming Venture Partners and SDIC Chuanghe. Existing shareholders, including YuanBio Venture Capital, LYFE Capital, Tasly Capital, and Optimas Capital, continued to participate in the follow-on investment.

The proceeds from this round of financing will be used to support the implementation of end-to-end digital solutions for artificial joints and product solutions for cartilage repair.

Public records indicate that this financing represents the largest single funding round in the joint sector in recent years.ThisThis not only demonstrates the capital market’s recognition of Just Medical’s continuous innovation system, but also proves that there is significant room for growth in the industry where Just Medical operates.

Mr. Liu Nian, Chairman of Just Medical, stated: ““We extend our gratitude to leading investment institutions for their trust and for endorsing the Company’s long-term commitment to building an ecosystem for joint disease prevention and treatment, maintaining a customer-centric approach, and driving value creation through innovation. Looking ahead, the Company will continue to focus on stepped care for joint diseases, sustain investments in innovative platforms such as artificial intelligence, 3D printing, new material applications, and regenerative medicine, accelerate innovation cycles, and deliver diversified, higher-quality products and services to patients.”

According to available information, Just Medical focuses on joint diseases, dedicated to enhancing the well-being of patients with joint conditions and reducing societal healthcare costs. The company has established and refined a stepped-care product solution for joint diseases, fostering a harmonious ecosystem for joint disease treatment.

Driven by product innovation, Just Medical has achieved a compound annual growth rate (CAGR) of over 50% in product sales for three consecutive years. In terms of market promotion, Just Medical has established a nationwide sales network across China and exported its products to nearly 20 countries and regions overseas.

An overview of Just Medical’s core strengths reveals that its robust innovation, R&D, and commercialization capabilities are the source of strong confidence among numerous renowned investment institutions.

Official data shows that,Just Medical has established a dual-platform system for medical-engineering interaction in artificial joints—the 3D JCT Medical-Engineering Interaction Center and the Enterprise Key Laboratory. This framework creates a collaborative and communicative bridge among hospitals, clinicians, research institutions, and universities, facilitating more innovative medical-engineering partnership projects and enabling the development of new technologies, materials, and products with international competitiveness.

Leveraging a convenient medical-engineering interaction platform, Just Medical has developed the world’s first trabecular femoral stem and trabecular total hip joint. Both the acetabular and femoral components of the trabecular total hip joint feature trabecular structures fabricated using 3D metal printing technology. This achieves a qualitative improvement in bone ingrowth performance, overcomes the mechanical strength limitations of printed components, and perfectly combines osteoinductive properties with mechanical strength.The first and only product of its kind to be launched globally.

Just Medical has also developed a mobile-bearing unicompartmental knee prosthesis system. The advantages of this product include the preservation of both anterior and posterior cruciate ligaments during partial replacement, elimination of the need for soft tissue balancing, and completion via minimally invasive surgery, thereby providing Chinese patients with an effective treatment option aligned with cultural preferences.Notably, the product is expected to receive approval in the near future. Once approved, it will fill the domestic gap for locally manufactured products, providing Chinese patients with a homegrown alternative.

The 3D Trabecular Biological Knee Prosthesis System is also a strategically developed product by Just Medical, filling a domestic gap. This product addresses the issue of immediate prosthetic stability while simultaneously achieving long-term stability. Just Medical stated: “The 3D Trabecular Biological Knee Prosthesis System, once launched, will revolutionize global knee fixation methods.”

Based on keen insights into market and industry development trends, Just Medical has also proactively planned its strategic layout to seize first-mover advantages. For instance, Just Medical is the first artificial joint company in China to deploy surgical robots. Its EPS joint surgery robot aims to transform the current landscape of joint surgery by making procedures more accessible, enabling more orthopedic surgeons to master surgical techniques, and delivering more stable and precise outcomes for patients. Additionally, Just Medical is the first artificial joint company in China to implement intelligent manufacturing. The first phase of its intelligent demonstration factory for artificial joints, with an investment of hundreds of millions of yuan, was officially launched in June 2021, expected to increase production efficiency fivefold and enhance competitive advantage. Furthermore, Just Medical is also the first artificial joint company in China to venture into cartilage regenerative medicine, having already developed products such as injectable cartilage repair agents.

It is precisely due to its strategic vision and innovative R&D capabilities that Just Medical has developed multiple products that are global firsts and fill gaps in the domestic market, thereby earning the favor and recognition of the capital markets. Numerous investment institutions have full confidence in Just Medical and are willing to be “friends of time,” accompanying the company in its shared growth.

Currently, Just Medical has established the Tianjin Key Enterprise Laboratory for Functionalization and Personalized Research of Bone Implant Interfaces. The company has obtained 14 Class III medical device registration certificates issued by the NMPA, filed a total of 152 patent applications, including 73 invention patent applications, with 16 invention patents granted.

Amidst continuous innovation and rapid development, Just Medical has gained recognition from the government, capital markets, and experts. The company has been successively recognized as a National High-Tech Enterprise, a Leading Enterprise in Tianjin’s Strategic Emerging Industries, a Tianjin Gazelle Enterprise, a Pilot Unit for Intellectual Property in Tianjin, a Famous Trademark in Tianjin, and an Undertaking Unit for Tianjin Enterprise Key Laboratories. It has also consecutively undertaken multiple major special projects in biomedical engineering science and technology in Tianjin, as well as key technological support projects under Tianjin’s Key R&D Program.

Zhang Ao, Executive Director of Qiming Venture PartnersIndicates：““Focusing on the artificial joint sector and continuously increasing R&D investment are key reasons why Qiming Venture Partners is bullish on Just Medical. Building on its existing product portfolio, Just Medical has been optimizing product designs and developing differentiated new products, including mobile-bearing unicompartmental knee implants, a full range of 3D-printed products, and surgical robots. The company has also made strategic forays into regenerative medicine and new material research and development. Overall, the team is pragmatic and execution-oriented, delivering significant project outcomes. We believe the Chinese market for orthopedic artificial joints holds immense potential.”

SDIC ChuangheIt stated: “While continuously increasing R&D investment, the company is constantly optimizing its management to improve quality and efficiency. The deployment of artificial intelligence and smart factories fully demonstrates Just Medical’s determination and confidence in deepening its industry presence. During our visit to the smart factory, we observed that the planning for the company’s key laboratory was very clear, with ample preparations made for the upcoming CNAS laboratory accreditation. We hope that the participation of SDIC Chuanghe will help the company integrate more high-quality resources and accelerate its rapid development.”

Yin Jie, Partner at YuanBio Venture Capitalstated: “With the aging of the global population and the improvement of people’s living standards, arthritis patients are becoming aware of the need for prevention and treatment at an earlier stage. Just Medical’s R&D layout in recent years aligns with the broader direction of market development. We firmly believe that Just Medical will rapidly become a leading enterprise in this niche market. We look forward to working with such outstanding companies to promote the rapid development of China’s healthcare industry.”

Yu Zhengkun, Founding Partner of Jifeng Capitalstated: “In the face of intense competition and unfavorable policy conditions in the domestic market, the company proactively planned its strategic layout, successfully establishing an integrated strategy combining joint robots with consumables. This approach has accelerated the launch of new products while driving innovative iterations of existing ones. While continuously strengthening its innovation and R&D capabilities, the company has also made significant progress in market expansion, achieving sales in more than 20 countries and regions worldwide. We will continue to support the company’s rapid development and growth.”

Ma Qiang, General Manager of Tasly Capitalindicate：“Congratulations to Just Medical on successfully securing hundreds of millions in financing. As China’s population aging accelerates, the number of orthopedic patients, particularly those requiring knee arthroplasty, continues to rise. Just Medical’s 3D-printed product series and AI-powered surgical robots are poised for significant growth opportunities. Wishing Just Medical great success in its future endeavors!

Qiming Venture Partners, established in 2006, has successively set up offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages nine US dollar funds and six RMB funds, with total assets under management reaching $5.9 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage enterprises in sectors such as TMT and Healthcare. To date, Qiming Venture Partners has invested in over 380 high-growth innovative companies, among which more than 130 have achieved exits through listings on exchanges including the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange, the Taipei Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, as well as through mergers and acquisitions. Additionally, over 40 of these portfolio companies have become industry-recognized unicorns and super unicorns.

SDIC Chuanghe is the professional guidance fund and industrial fund management arm of SDIC Group. It currently manages two national-level funds, along with multiple industrial and market-oriented funds, with directly managed assets exceeding RMB 40 billion. Focusing on equity investment, venture capital, and fund-of-funds investments in strategic emerging industries, SDIC Chuanghe has over 80 direct investment projects under management and holds stakes in more than 170 funds. It has nurtured over 2,600 innovative technology enterprises, becoming the guidance fund management institution in China that supports the largest number of venture capital teams and covers the widest range of industries. Under the advocacy of the National Development and Reform Commission, SDIC Chuanghe also took the lead in establishing the National Venture Capital Service Alliance for Innovative Biopharmaceuticals, Artificial Intelligence, New Materials, and Cybersecurity, continuously improving the investment ecosystem, pooling the collective strength of mass entrepreneurship and innovation, and promoting the development of emerging industries.